These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16281428)

  • 21. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonconventional clinical trial designs: approaches to provide more precise estimates of treatment effects with a smaller sample size, but at a cost.
    Howard G
    Stroke; 2007 Feb; 38(2 Suppl):804-8. PubMed ID: 17261743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
    Cellamare M; Sambucini V
    Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The sample size for a clinical trial: a Bayesian-decision theoretic approach.
    Halpern J; Brown BW; Hornberger J
    Stat Med; 2001 Mar; 20(6):841-58. PubMed ID: 11252007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian methods for the design and analysis of noninferiority trials.
    Gamalo-Siebers M; Gao A; Lakshminarayanan M; Liu G; Natanegara F; Railkar R; Schmidli H; Song G
    J Biopharm Stat; 2016; 26(5):823-41. PubMed ID: 26247350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.
    Tidwell RSS; Peng SA; Chen M; Liu DD; Yuan Y; Lee JJ
    Clin Trials; 2019 Dec; 16(6):645-656. PubMed ID: 31450957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian methods for pilot studies.
    Willan AR; Thabane L
    Clin Trials; 2020 Aug; 17(4):414-419. PubMed ID: 32297539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian sample size determination under hypothesis tests.
    Zhang X; Cutter G; Belin T
    Contemp Clin Trials; 2011 May; 32(3):393-8. PubMed ID: 21199689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian predictions of final outcomes: regulatory approval of a spinal implant.
    Lipscomb B; Ma G; Berry DA
    Clin Trials; 2005; 2(4):325-33; discussion 334-9, 364-78. PubMed ID: 16281431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing methods for calculating confidence intervals for vaccine efficacy.
    Ewell M
    Stat Med; 1996 Nov 15-30; 15(21-22):2379-92. PubMed ID: 8931208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens.
    Howard G; Coffey CS; Cutter GR
    Stroke; 2005 Jul; 36(7):1622-3. PubMed ID: 15947275
    [No Abstract]   [Full Text] [Related]  

  • 37. Bayesian sample-size determination methods considering both worthwhileness and unpromisingness for exploratory two-arm randomized clinical trials with binary endpoints.
    Kakizume T; Zhang F; Kawasaki Y; Daimon T
    Pharm Stat; 2020 Jan; 19(1):71-83. PubMed ID: 31496045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.
    Yin G; Chen N; Lee JJ
    Stat Biosci; 2018 Aug; 10(2):420-438. PubMed ID: 30559900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian methods in health technology assessment: a review.
    Spiegelhalter DJ; Myles JP; Jones DR; Abrams KR
    Health Technol Assess; 2000; 4(38):1-130. PubMed ID: 11134920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?
    Iorio A; Marcucci M
    Haemophilia; 2009 Jul; 15(4):900-3. PubMed ID: 19473413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.